Stock REGN REGENERON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
980.6 USD -0.33% Intraday chart for Regeneron Pharmaceuticals, Inc. +1.30% +11.65%
May. 23 Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer MT
May. 22 Regeneron Pharmaceuticals Insider Sold Shares Worth $1,855,489, According to a Recent SEC Filing MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
GL
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
PR
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
GL
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
AQ
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
AQ
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
GL
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
BU
The Interplay: Key Decisions At The Intersection Of Antitrust & Life Sciences - April 2024
AQ
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
GL
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
AQ
REGENERON PHARMACEUTICALS - LATEST DB-OTO RESULTS SHOW DRAMATICALLY IMPROVED HEARING TO NORMAL LEVELS IN A CHILD WITH PROFOUND GENETIC DEAFNESS WITHIN 24 WEEKS AND INITIAL HEARING IMPROVEMENTS IN A SECOND CHILD AT 6 WEEKS
AQ
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
GL
Regeneron Announces Investor Conference Presentations
GL
Regeneron Pharmaceuticals : May 2024 Corporate Presentation
PU
Regeneron: Q1 Earnings Snapshot
AQ
Regeneron Reports First Quarter 2024 Financial and Operating Results
GL
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
GL
DOJ Files False Claims Act Complaint Against Regeneron, Alleging Fraudulent Eylea Drug Pricing
AQ
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
GL
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. REGN Stock
  4. News Regeneron Pharmaceuticals, Inc.
  5. Press Releases